First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma.

@article{Zhu2013FirstinmanPI,
  title={First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma.},
  author={Andrew X. Zhu and Philip Jordan Gold and Anthony B El-Khoueiry and Thomas Adam Abrams and Hideo Morikawa and Norihisa Ohishi and Toshihiko Ohtomo and Philip Agop Philip},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2013},
  volume={19 4},
  pages={920-8}
}
PURPOSE GC33 is a novel recombinant fully humanized monoclonal antibody that binds to human glypican-3 (GPC3). The antitumor activity of GC33 was shown in preclinical models of hepatocellular carcinoma (HCC). This first-in-man clinical trial was conducted to evaluate the safety, pharmacokinetic characteristics, and preliminary efficacy of GC33 in patients with advanced HCC. EXPERIMENTAL DESIGN Patients with measurable, histologically proven, advanced HCC were enrolled to a dose-escalation… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 45 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 28 references

Generation of a humanized anti - glypican 3 antibody by CDR grafting and stability optimization

  • T Ishiguro, M Sugimoto, Y Kinoshita, Y Miyazaki, K Nakano, H Tsunoda
  • Anticancer Drugs
  • 2010

Similar Papers

Loading similar papers…